Search Results

The product title you are looking for is no longer available. Other similar products that may interest you are listed below:

Refine your Search

Results for 'Astellas'
Title Publication Date Price Relevance
IMS Company Profiles:Astellas Nov 2011 £640 100%
Pharma Company Profiles - Astellas Pharma Oct 2008 £255 99%
Astellas: Pipeline, Products, Performance, Potential Jan 2010 £595 99%
Astellas Pharma Canada, Inc.-Detailed Product Pipeline Mar 2011 £475 99%
Astellas Pharma Inc.-Therapeutic Competitors Report Mar 2011 £220 99%
Astellas Pharma Taiwan, Inc-Therapeutic Competitors Report Mar 2011 £220 98%
Astellas Pharma Korea, Inc.-Therapeutic Competitors Report Mar 2011 £220 98%
Astellas Pharma Canada, Inc.-Therapeutic Competitors Report Mar 2011 £220 98%
Astellas Pharma China Inc.-Therapeutic Competitors Report Mar 2011 £220 98%
Astellas Pharma US, Inc.-Therapeutic Competitors Report Mar 2011 £220 98%
Astellas Pharma Inc.-Deals & Alliances Report Mar 2011 £380 98%
Astellas Pharma Hong Kong Co., Ltd-Therapeutic Competitors Report Mar 2011 £220 98%
Astellas Pharma Inc.: PharmaVitae Profile Jun 2010 £3,605 97%
Partnering Agreements with Astellas 2010 Jan 2010 £630 97%
Astellas Pharma Inc. – Product Pipeline Review
H2 2011
 Nov 2011 £315 95%
Pharmaceuticals in Singapore Jan 2011 £160 90%
Pharmaceuticals in Japan Jan 2011 £160 90%
Pharmaceuticals in Asia-Pacific Jan 2011 £160 89%
Biotechnology in Asia-Pacific Sep 2011 £160 89%
Theravance, Inc. – Product Pipeline Review
H2 2011
 Nov 2011 £315 86%
Overactive Bladder (OAB) Therapeutics Aug 2011 £2,845 84%
The Pharmaceutical Market: Japan Oct 2011 £595 83%
Ambit Biosciences Corporation – Product Pipeline Review
H2 2011
 Nov 2011 £315 82%
The Global Antibacterials Market
R&D Pipelines, Market Analysis and Competitive Landscape
 Aug 2007 £1,580 82%
Licensing Strategies of Large Pharmaceutical Companies
Weak R&D Pipelines and The Patent Cliff Stimulate in-Licensing Activity
 Sep 2011 £2,215 81%
Ependymoma Global Clinical Trials Review
Q4, 2010
 Dec 2010 £630 81%
MorphoSys AG – Product Pipeline Review
H2 2011
 Nov 2011 £315 81%
CoMentis, Inc. – Product Pipeline Review
H2 2011
 Dec 2011 £315 80%
Pharma Sales World 2007
Advanced Sales Force Remodelling Strategies in a Multi-Channel Environment
 Jan 2008 £75 80%
Overactive Bladder - Pipeline Review
H2 2011
 Oct 2011 £315 80%